

Medis QFR[®] 2.2

Physiology made **simple.**

Image-based coronary physiology powered by AI deep learning

Clinical evidence

The angio-based solution supported by the greatest number of peer-reviewed scientific publications¹.

User friendly

Simple & intuitive workflow, applicable for in-procedure as well as retrospective analysis.

Time & cost efficiency

No pressure wire, no adenosine. Reduces treatment costs and procedure time.

Eccentric lesions

Accurate even in the case of eccentric lesions.

What's new in Medis QFR[®] 2.2?

Simpler, faster, minimally invasive coronary physiology

Fast ED frame detection powered by AI

The optimal ED frame is automatically detected by Artificial Intelligence, based on the best contrast filling.

Improved flow velocity calculations


Reduces the number of manual interactions.

Automatic matching of 2 views

The offset correction step is now automated.

Clinical report

In Medis QFR[®], reports are made available in two formats: Essential and Advanced.



Exceptional **performance**

3x

3-fold decrease in the risk of adverse events associated with a post-PCI cut off value > 0.89²

32%

Reduction in MACE compared to standard visual angiography guidance after 2 years³

30%

Faster than wire-based FFR guided approach⁴

Medis QFR[®] 2.2

Physiology made **simple.**

Image-based coronary physiology powered by AI deep learning

Analysis time **<60 seconds** per vessel

- dQFR/ds helps establish the presence or absence of focal disease.
- QFR-IMR calculations, available in the research edition, offer insights into microcirculatory dysfunction with more automated flow velocity calculations
- Residual QFR helps simulate post-PCI FFR values.^{5,6}

What **experts** say about Medis QFR[®]

“QFR[®] streamlines the Cath Lab workflow, increasing the adoption of coronary physiology. The benefits are the cost effectiveness as well as the time efficiency.

Dr. Yuhei Kobayashi

New York Presbyterian Hospital, United States
Interventional cardiologist / Cardiologist



“This technique is simpler, safer and less expensive with equivalent outcomes and will conceivably be readily and widely adopted.

Dr. Morton J. Kern

University of California, United States
Interventional cardiologist / Cardiologist



“State-of-the-art approach in acute coronary syndrome targets on the “pancoronary risk”. This can be assessed easily, safely and reproducibly by QFR[®].

Dr. David M. Leistner

Universitätsklinikum Frankfurt am Main, Germany
Interventional cardiologist / Cardiologist



“QFR[®] is a robust technology and it provides good diagnostic data and guiding information.

Dr. Niels Holm

Aarhus University, Denmark
Clinical Researcher



References

1. EuroIntervention 2023. Expert Consensus: <https://eurointervention.pconline.com/doi/10.4244/EIJ-D-23-00194>
2. Biscaglia, S., Tebaldi, M., Brugaletta, S., Cerrato, E., Erriquez, A., Passarini, G., Ielasi, A., Spitaleri, G., Di Girolamo, D., Mezzapelle, G., Geraci, S., Manfrini, M., Pavasini, R., Barbato, E., & Campo, G. (2019). Prognostic Value of QFR Measured Immediately After Successful Stent Implantation: The International Multicenter Prospective HAWKEYE Study. *JACC. Cardiovascular interventions*, 12(20), 2079–2088. <https://doi.org/10.1016/j.jcin.2019.06.003>
3. Song L. et al., 2-Year Outcomes of Angiographic Quantitative Flow Ratio-Guided Coronary Interventions. *J Am Coll Cardiol*. 2022 Nov, 80 (22) 2089–2101
4. Westra J. et al., Diagnostic Performance of In-Procedure Angiography-Derived Quantitative Flow Reserve Compared to Pressure-Derived Fractional Flow Reserve: The FAVOR II Europe-Japan Study. *J Am Heart Assoc*. 2018. DOI: 10.1161/JAHA.118.009603
5. Lee H. et al., Prediction of functional results of percutaneous coronary interventions with virtual stenting and quantitative flow ratio. *CCI* (2022). <https://doi.org/10.1002/ccd.30451>
6. Diemen P. et al., Residual Quantitative Flow Ratio to Estimate Post-Percutaneous Coronary Intervention Fractional Flow Reserve. *Journal of Interventional Cardiology* (2021). Volume 2021 | Article ID 4339451 | <https://doi.org/10.1155/2021/4339451>

Legal Statements

Medis and QAngio are registered trademarks of Medis Associated by.

QFR is a registered trademark of QFR Solutions by Medis Suite and QAngio XA have market clearance for USA, Canada, EU, Australia, South Korea, and Saudi Arabia.

QAngio XA 3D (incl. QFR), has market clearance for the USA, Canada, EU, Japan, Australia, Brazil, Malaysia, Singapore, Indonesia, South Korea, Turkey and Saudi Arabia.